



# A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

25/11/2024 08:31:13

## Main Information

### Primary registry identifying number

LBCTR2019030190

### Protocol number

CBYL719C2301

### MOH registration number

7829/ص

### Study registered at the country of origin

Yes

### Study registered at the country of origin: Specify

### Type of registration

Retrospective

### Type of registration: Justify

LCTR was recently initiated, original file was previously submitted by Paper

### Date of registration in national regulatory agency

27/08/2015

### Primary sponsor

Novartis Pharma Services Inc.

### Primary sponsor: Country of origin

Novartis Pharmaceuticals

### Date of registration in primary registry

24/11/2020

### Date of registration in national regulatory agency

27/08/2015

### Public title

A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

### Acronym

SOLAR-1

### Scientific title

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

### Acronym

### Brief summary of the study: English

To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free survival compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer, who received prior treatment with an Aromatase Inhibitor either as (neo) adjuvant or for advanced disease

### Brief summary of the study: Arabic

: دراسة عشوائية التوزيع، مزدوجة التعمية، مضبوطة الدواء الوهمي في المرحلة الثالثة حول اليبليسب بالاشتراك مع فولفسترانت 1سولار - سلبي الذي تطوّر عند أو بعد - HER2 للرجال والنساء ما بعد انقطاع الطمث المصابين بسرطان الثدي المتقدم مع مستقبل هورمون إيجابي علاج بمثبط للأروماتاز



**Health conditions/problem studied: Specify**

men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

**Interventions: Specify**

IMP : BYL719 Alpelisib

**Key inclusion and exclusion criteria: Inclusion criteria**

## Inclusion Criteria:

- If female, patient is postmenopausal
- Patient has identified PIK3CA status
- Patients may be:
  - relapsed with documented evidence of progression while on (neo) adjuvant endocrine therapy or within 12 months from completion of (neo) adjuvant endocrine therapy with no treatment for metastatic disease;
  - relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently; progressed with documented evidence of progression while on or after only one line of endocrine therapy for metastatic disease;
  - newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy
- Patient has recurrence or progression of disease during or after AI therapy (i.e.

letrozole, anastrozole, exemestane).

- Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by local laboratory and has HER2 negative breast cancer
- Patient has either measurable disease per RECIST 1.1 criteria OR at least one predominantly lytic bone lesion must be present
- Patient has adequate bone marrow function

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender****Key inclusion and exclusion criteria: Age minimum**

18

**Key inclusion and exclusion criteria: Age maximum**

99

**Key inclusion and exclusion criteria: Exclusion criteria**

## Exclusion Criteria:

- Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment
- Patient has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor (pre-treatment with CDK4/6 inhibitors is allowed)
- Patient with inflammatory breast cancer at screening
- Patients with Child pugh score B or C
- Patients with an established diagnosis of diabetes mellitus type I or not controlled type II
- Patient has Eastern Cooperative Oncology Group (ECOG) performance status 2 or more
- Patient with CNS involvement unless he/she is at least 4 weeks from prior therapy completion to starting the study treatment and has stable CNS tumor at time of screening and not receiving steroids and/or enzyme inducing ant-epileptic medications for brain metastases
- Patient has participated in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
- Patient has a history of acute pancreatitis within 1 year of screening or a past medical history of chronic pancreatitis
- Patient who relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease

Other protocol-defined inclusion/exclusion criteria may apply

**Type of study**

Interventional

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

N/A

**Trial scope**

Therapy

**Trial scope: Specify scope**

N/A

**Study design: Allocation**

Randomized controlled trial

**Study design: Masking**

Blinded (masking used)

**Study design: Control**

Placebo

**Study phase**

3

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Parallel

**Study design: Specify assignment**

N/A

**IMP has market authorization**

No

**IMP has market authorization: Specify****Name of IMP**

BYL719 ( ALpelisib)

**Year of authorization****Month of authorization****Type of IMP**

Others

**Pharmaceutical class**

$\alpha$ -specific class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2-aminothiazole class of compounds.

**Therapeutic indication**

hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

**Therapeutic benefit**

Progression-free survival (PFS) [ Time Frame: Up to approximately 36 months ]

Overall survival (OS) for patients with PI3KCA mutant status [ Time Frame: Up to approximately 59 months ]

Overall response rate (ORR) [ Time Frame: Up to approximately 36 months ]

Time to definitive deterioration of Eastern Cooperative Oncology Group (ECOG) performance status

[ Time Frame: Baseline, Up to approximately 36 months ]

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration****Target follow-up duration: Unit****Number of groups/cohorts****Biospecimen retention**

Samples without DNA

**Biospecimen description**



Blood, urine and Tissue samples shipped to Quintiles central Lab or Genoptix BioPharma Lab in the UK ; Laboratory (Hematology, chemistry, biomarkers, pharmacokinetics), Urinalysis shipped to Quintiles (Q2) central Lab in the UK and Tissue Slides sent to Genoptix Central Lab in the UK

**Target sample size**

8

**Actual enrollment target size**

8

**Date of first enrollment: Type**

Actual

**Date of first enrollment: Date**

16/02/2016

**Date of study closure: Type**

Actual

**Date of study closure: Date**

28/04/2022

**Recruitment status**

Complete

**Recruitment status: Specify****Date of completion**

09/06/2017

**IPD sharing statement plan**

Yes

**IPD sharing statement description**

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)

**Additional data URL**

<https://clinicaltrials.gov/ct2/show/NCT02437318?term=CBYL719C2301&rank=1>

**Admin comments****Trial status**

Approved

## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
National Institute of Health (clinicaltrials.gov)	NCT02437318

## Sources of Monetary or Material Support

Name
Novartis Pharma Services Inc.



## Secondary Sponsors

Name

NA

## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Joseph Kattan	Beirut	Lebanon	009613635913	jkattan62@hotmail.com	Hotel Dieu De France
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Fadi El Karak	Mansourieh	Lebanon	+961 3 061 621	felkarak@yahoo.com	Bellevue Medical Center
Public	Fadi Farhat	Saida	Lebanon	+9613753155	drfadi.trials@gmail.com	Hammoud Hospital

## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hammoud Hospital University Medical Center	Dr Fadi Farhat	Hematology Oncology	Approved
Bellevue Medical Center	Dr Fadi El Karak	Hematology Oncology	Approved
Hotel Dieu De France	Dr Joseph Kattan	Hematology Oncology	Approved

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	01/06/2015	Nancy Alam	nancy.alam@usj.edu.lb	+961 (0) 1 421000 ext 2335
Bellevue Medical Center	04/09/2015	Ghassan Maalouf	gmaalouf@bmc.com.lb	+961 (0) 1 682666 ext 7600
Hammoud Hospital University Medical Center	05/08/2015	Ahmad Zaatari	zaatari@hammoudhospital.com	+961 (0) 7 723111 ext 1160



## Countries of Recruitment

Name
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
Lebanon
China
Germany
Italy
France
India

## Health Conditions or Problems Studied

Condition	Code	Keyword
Advanced Breast Cancer	Breast, unspecified (C50.9)	ABC

## Interventions

Intervention	Description	Keyword
Laboratory (Hematology, chemistry, biomarkers, pharmacokinetics), Urinalysis, ECG, Echocardiogram, Physical Exma, Vital Signs	Lab, ICF, ECG, IMP administration	ICF, Lab, ECG, IMP

## Primary Outcomes

Name	Time Points	Measure
Progression-free survival (PFS) for patients with PIK3CA mutant status	Up to approximately 36 months	36 Months



## Key Secondary Outcomes

Name	Time Points	Measure
Overall survival (OS) for patients with PI3KCA mutant status	59 months	59 months
Overall response rate (ORR)	36 months	36 months

## Trial Results

**Summary results**

**Study results globally**

**Date of posting of results summaries**

**Date of first journal publication of results**

**Results URL link**

**Baseline characteristics**

**Participant flow**

**Adverse events**

**Outcome measures**

**URL to protocol files**